Clinical Trials Logo

Immune Thrombocytopenia (ITP) clinical trials

View clinical trials related to Immune Thrombocytopenia (ITP).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04669600 Completed - Clinical trials for Immune Thrombocytopenia (ITP)

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

Start date: February 4, 2021
Phase: Phase 2
Study type: Interventional

Primary Objective: - To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP) Secondary Objectives: - To assess the safety and tolerability of BIVV020 - To assess the pharmacokinetics of BIVV020 - To assess the response rate of treatment with BIVV020 - To assess the time to response - To assess the effect of treatment with BIVV020 on the requirement for rescue ITP therapy - To assess the immunogenicity of BIVV020

NCT ID: NCT04346654 Completed - Clinical trials for Immune Thrombocytopenia (ITP)

A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP

XPAG-ITP
Start date: October 9, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the ability of eltrombopag in combination with a short course of high-dose dexamethasone to induce sustained response off treatment in patients with newly-diagnosed ITP versus 1-3 cycles of dexamethasone monotherapy. The unmet clinical need and the potential for eltrombopag when added to steroids to improve the treatment outcome and the potential to induce sustained response off treatment serve as the basis for clinical investigation of eltrombopag in first-line ITP.

NCT ID: NCT02868060 Completed - Clinical trials for Immune Thrombocytopenia (ITP)

Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)

Start date: September 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of evaluating the pharmacokinetics and pharmacodynamics of romiplostim in patients with immune thrombocytopenia.

NCT ID: NCT01666795 Completed - Clinical trials for Immune Thrombocytopenia (ITP)

Autoantibody Specificity and Response to IVIG in ITP

Start date: February 2005
Phase: N/A
Study type: Observational

The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment.

NCT ID: NCT00344149 Completed - Clinical trials for Immune Thrombocytopenia (ITP)

Rituximab as Second Line Treatment for ITP

Start date: June 2006
Phase: Phase 3
Study type: Interventional

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized thrombocytopenia. Splenectomy is the standard treatment for patients who fails the first-line treatment: corticosteroid. Rituximab, has recently emerged as a promising treatment for ITP. The aim of the study is to determine whether early treatment with Rituximab can result in durable remissions, and consequently, lead to the avoidance of splenectomy in a significant number of patients.